|
Urgent Updates
March 29, 2007: Permax (generic: pergolide) Pulled From The Market By The FDA
April 24, 2007: Dostinex (generic: cabergoline) Pulled From The Market By The FDA)
The FDA has asked the manufacturers of pergolide and cabergoline to withdraw these drugs from the market due to the potential for heart valve damage. Two recent studies showed that patients with Parkinson's disease who were treated with pergolide or cabergoline had an increased chance of serious damage to their heart valves when compared to patients who did not receive either drug.
|
| Serious Adverse Effects |
| | Cardiac Valve Damage / Heart Valve Damage |
| | Cardiac Valve Regurgitation |
Findings from two European studies published in the New England Journal of Medicine the week of January 1, 2007 show that two dopamine agonist drugs used to treat the symptoms of Parkinson's disease and Restless Leg Syndrome may raise the risk of cardiac valve damage and cardiac valve regurgitation.
According to the studies, while taking other dopamine agonists seemed to have no effect on the risk of cardiac valve regurgitation, use of Permax or Dostinex raised the risk of valve regurgitation by 7.1- and 4.9-fold, respectively.
Cardiac valve regurgitation occurs when the heart valve fails to seal properly in the reverse-flow direction.
If you or someone you know has taken Permax or Dostinex and suffered any of the problems described above, contact us today.
Your time may be short to collect compensatory or punitive damages for your serious injuries. If you, your family or someone you know has been injured, email us now for a free, private consultation. Knowledge is power- we'd like to help you!
Contact us today at Info@HelpingTheInjured.com
| 
